CLL Furman et al. (2014) reported on a study of patients with recurring chronic lymphocytic leukemia (CLL). The study was randomized, double-blind, and placebo-controlled. After 12 months, 101 of the 110 patients assigned to the combination treatment of idelalisib (idel) with rituximab (rit) were still alive, and 88 of the 110 patients assigned to placebo with rit were still alive. Perform a hypothesis test to test whether those who take idel have a better chance of surviving than those taking the placebo. Use a level of significance of 0.05. Can we conclude that idel causes an increased chance of survival? See page 406 for guidance.